Advertisement

Pharmaceutical Chemistry Journal

, Volume 52, Issue 3, pp 195–197 | Cite as

Possible Ways of Studying Pharmacokinetic Parameters of Calcium Preparations

  • N. N. Eremenko
  • E. V. Shikh
  • S. Yu. Serebrova
  • D. V. Goryachev
Article
  • 28 Downloads

Issues pertaining to determination of the pharmacokinetic parameters of calcium preparations are examined using their comparative bioavailability as an example. Pharmacokinetic parameters of calcium such as area under the concentration—time curve (AUC) and maximum concentration (Cmax) are calculated considering the background calcium contents in volunteers. Calcium excretion with urine is assessed as clearance of creatinine, a calcium elimination factor. The dynamics of the content of parathormone (PTH), the main hormone regulating calcium homeostasis, are studied. The results can be used to plan clinical trials for assessing the pharmacokinetics of drug analogs of endogenous compounds.

Keywords

comparative pharmacokinetics clinical trials in vivo endogenous compounds calcium calcium-creatinine coefficient parathormone 

References

  1. 1.
  2. 2.
    L. Fialova and M. Vejrahka, Metabolism of Calcium and Phosphorus, Prague (2010 / 2011).Google Scholar
  3. 3.
    M. Peacock, Clin. J. Am. Soc. Nephrol., 5, S23 – S30 (2010).CrossRefPubMedGoogle Scholar
  4. 4.
    Human Vitamin and Mineral Requirements. Report of a Joint FAO / WHO Expert Consultation, World Health Organization, Bangkok, Thailand (2001), p. 303.Google Scholar
  5. 5.
    E. V. Shikh and A. A. Makhova, Eff. Farmakoter., 36, 24 – 30 (2013).Google Scholar
  6. 6.
    B. G. Iskanderov, Arterial Hypertension and Calcium Metabolism [in Russian], Penza (2010), p. 225.Google Scholar
  7. 7.
    A. N. Mironov, Guide to Drug Review [in Russian], Vol. 1, Moscow (2013), p. 323.Google Scholar
  8. 8.
    Rules of Carrying Out Research of Bioequivalence of Medicines Within the Eurasian Economic Union, approved by a Decision of Council of the Eurasian Economic Commission of Nov. 3, 2016, No. 85, Moscow (2016).Google Scholar
  9. 9.
    Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA, United States Food and Drug Administration, New Hampshire (2013).Google Scholar
  10. 10.
    Investigation of Bioequivalence (CPMP / EWP / QWP / 1401 / 98 Rev. 1), European Medicines Agency, London (2013).Google Scholar
  11. 11.
    P. Colucci, M. Pasternyk-Di Marco, D. Potvin, et al., Generic Drug Product Development: Bioequivalence Issues, Boca Raton (2007), pp. 233 – 256.Google Scholar
  12. 12.
    S. Dissanayake, Br. J. Clin. Pharmacol., 69(3), 238 – 244 (2010).CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    J. Gabrielsson and D. Weiner, Am. J. Pharm. Educ., 74(3), 1250 (2010).Google Scholar
  14. 14.
    N. N. Eremenko, D. V. Goryachev, and E. V. Shikh, Vedom. Nauchn. Tsentra Eksp. Sredstv Med. Primen., 7(2), 104 – 110 (2017).Google Scholar
  15. 15.
    A. Marzo, Ital. J. Med., 7(3), 156 – 159 (2013).CrossRefGoogle Scholar
  16. 16.
    A. Marzo, Pharmacol. Res., No. 40, 357 – 368 (1999).Google Scholar
  17. 17.
    G. Kressel, M. Wolters, and A. Hahn, Food Nutr. Sci., 1, 53 – 58 (2010).Google Scholar
  18. 18.
    N. N. Eremenko, E. V. Shikh, and S. Yu. Serebrova, Patogenez, 14(4), 69 – 73 (2016).Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • N. N. Eremenko
    • 1
    • 2
  • E. V. Shikh
    • 1
    • 2
  • S. Yu. Serebrova
    • 1
    • 2
  • D. V. Goryachev
    • 1
  1. 1.Scientific Center for Expert Evaluation of Medicinal ProductsMinistry of Public Health of the Russian FederationMoscowRussia
  2. 2.Sechenov First Moscow State Medical UniversityMoscowRussia

Personalised recommendations